Back

Allogenic Megakaryocyte Therapy in patients with Refractory Thrombocytopenia

2025-10-09 hematology Title + abstract only
View on medRxiv
Show abstract

BACKGROUNDPatients with refractory thrombocytopenia (RT) are not sensitive to conventional therapies, such as platelet transfusions and thrombopoietin receptor agonists (TPO-RAs). The persistently high risk of life-threatening hemorrhage in this population highlights the urgent need for novel therapeutic strategies. Megakaryocyte (MK)-based therapies have emerged as a promising alternative, as MKs are the natural precursor cells responsible for platelet production. However, whether allogeneic MK...

Predicted journal destinations